文献速递眼底病与葡萄膜炎

DRCRnet糖尿病黄斑水肿临床试验入组时的种族和民族差异

Racial and Ethnic Disparities at Enrollment in DRCRnet Clinical Trials for Diabetic Macular Edema.
PubMed 文献 · Am J Ophthalmol · 2025-02-26

该回顾性横断面分析纳入17项DRCRnet糖尿病黄斑水肿(DME)试验的5468名受试者(2003—2020年),比较其种族民族构成与美国 census 及CDC VEHSS数据,发现白人(76%)过代表、亚裔(2%)和西班牙裔(12%)欠代表(P < .001);西班牙裔虽欠代表但HgbA1c更高、DR更重且VA更差。

要点

  • DME试验中白人占76%过代表,亚裔2%和西班牙裔12%欠代表(P < .001)。
  • 黑人和西班牙裔HgbA1c为8.3,高于白人7.7和亚裔7.6(P < .001)。
  • 西班牙裔、女性、糖尿病诊断年龄较大和重度DR与更差VA独立相关(均P < .05)。

核心结论

  • 西班牙裔受试者虽欠代表,但HgbA1c更高、DR更重且VA更差,强调DME试验需要多样化招募。

研究设计与样本

  • 回顾性横断面分析,数据来自2003—2020年17项DRCRnet DME临床试验的5468名受试者。
  • 将DRCRnet DME试验受试者的种族民族分布与美国census数据及CDC VEHSS的DME患病率数据进行比较。
  • 采用广义线性模型比较不同种族民族组间的人口学、HgbA1c、DR严重程度和VA,并确定与VA相关的因素。

主要发现

  • 与VEHSS(白人64%、黑人16%、亚裔4%、西班牙裔14%)和2020年美国census(白人62%、黑人12%、亚裔6%、西班牙裔19%)相比,DME试验中白人(76%)过代表,亚裔(2%)和西班牙裔(12%)欠代表(P < .001)。
  • 黑人和西班牙裔受试者HgbA1c为8.3,高于白人7.7和亚裔7.6(P < .001)。
  • 亚裔(20%)和西班牙裔(23%)受试者中增殖性DR比例高于白人(19%)和黑人(15%)(P < .001)。
  • 西班牙裔、女性、糖尿病诊断年龄较大和重度DR与更差VA独立相关(均P < .05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess racial/ethnic disparities and association with diabetic macular edema (DME) characteristics at enrollment in DRCR Retina Network (DRCRnet) DME clinical trials. DESIGN: Retrospective, cross-sectional analysis of data from DRCRnet clinical trials. SUBJECTS: 5468 participants in 17 DRCRnet DME trials (2003-2020). METHODS: The racial and ethnic distribution of DRCRnet DME trial participants was compared to United States census data and DME prevalence data in the CDC's Vision and Eye Health Surveillance System (VEHSS). Generalized linear models were used for comparing demographics, HgbA1c, diabetic retinopathy (DR) severity, and visual acuity (VA) among racial/ethnic groups, and for determining factors associated with VA. MAIN OUTCOME MEASURES: Racial and ethnic distribution of DME trial participants; patient and ocular characteristics at enrollment. RESULTS: Compared to VEHSS (64% White, 16% Black, 4% Asian, 14% Hispanic) and the 2020 U.S. census (62% White, 12% Black, 6% Asian, 19% Hispanic), White (76%) participants were over-represented, and Asians (2%) and Hispanics (12%) were under-represented (P < .001) in DME trials. HgbA1c was higher in Black and Hispanic (8.3) than in White (7.7) and Asian (7.6) participants (P < .001). More Asian (20%) and Hispanic (23%) participants had proliferative DR than White (19%) and Black (15%) participants (P < .001). Hispanic ethnicity, female gender, older age at diabetes diagnosis, and severe DR were independently associated with worse VA (all P < .05). CONCLUSIONS: Hispanic participants, while under-represented, had higher HgbA1c, more severe DR, and worse VA than other groups, emphasizing the need for diverse recruitment in DME trials.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Li M, He J, Vanderbeek BL, et al. Racial and Ethnic Disparities at Enrollment in DRCRnet Clinical Trials for Diabetic Macular Edema. Am J Ophthalmol. 2025. PMID: 40020979. doi:10.1016/j.ajo.2025.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。